NOS Life Sciences Corp.

We have developed a therapeutic that reduces Parkinson's progression by 79%, enhances levodopa motor benefits by 100%, and reduces dyskinesia by 48%.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Málaga, Spain
  • Currency EUR
  • Founded April 2017
  • Employees 7
  • Incorporation Type C-corp
  • Website noslifesciences.com

Company Summary

Today, millions of patients are affected by neurological conditions that create a global economic burden in the hundreds of billions.

We aim to help patients with neurological chronic diseases with clear unmet needs in terms of quality of life and disease modifying potential.

To achieve this, we are committed to the research of neuro signaling molecules married with proprietary nano-technology-based delivery systems for improved efficacy.

Team

  • Pablo Inones
    CEO

    With an extensive managerial experience in large corporations including Sanofi HQ and Latam, in the areas of Strategy, Marketing and General Management, Pablo has formed a world-class team with renowned scientists and executives from Europe and USA to carry forward NOS Life Sciences.
    Academic background in Business, Strategy and Economics at Columbia Business School (USA), IAE Business School (Argentina) and Sankt Gallen University (Switzerland).

  • Fernando Rodriguez de Fonseca
    CSO

    Scientific background:
    - 283 scientific documents published.
    - 68 public research grants including FP7 consortium coordination and National
    Addiction Research Network Coordination.
    - 20 PhD Thesis mentored.
    - 15 patents (inc. LipeaTM).
    - 3 National research awards (inc. Esteve Foundation International Research Award).
    - 153 Works submitted to national or international conferences.

  • Ruben Henriquez
    COO

    - Strategist and manager in BigPharma: Novartis and Sandoz.
    - Design, launch and growth of therapeutics and diagnostics companies.
    - Negotiation of alliances with Big Pharma: J&J and PharmaMar for € 200 million.
    - Post-doctorate U.of Basel, Switzerland
    - Fellowship US Public Health Service
    - PhD in Molecular Biology, Rockefeller U. New York (US)
    - MBA, IE Business School Madrid (Spain)
    - Biochemistry, Complutense U. Madrid (Spain)

  • Tina Garyantes
    Drug Development & Licensing

    - Global executive and therapeutic strategist for Big Pharma: Sanofi and Merck
    - Former founder and CEO of mid-size biotech company
    - Strong expertise in advancing drugs through clinical phases
    - Licensing-out and co-development agreements structuring, between emerging biotechs and Big Pharma
    - Doctorate in Biophysics, Caltech (US)
    - BSE in Bioengineering, U. Pennsylvania (US)
    - Benjamin Franklin Scholar
    - 18 scientific papers
    - 17 patents

  • Alcides Nicastro
    Bio-Engineering Director

    Scientific background:
    - 5 scientific documents published.
    - 2 research grants (CONICET)
    - 2 patents
    Academic background:
    - University of Litoral (Argentina): Doctorate in Biological Sciences
    - University of Litoral (Argentina): Master in Biotechnology
    - University of Litoral (Argentina): Bachelor in Chemistry
    Fields of Expertise:
    - Liposomal encapsulation for Oral Administration
    - Computational molecular simulations of interfaces.

  • Andy Maier
    Marketing Director

    Academic Background
    - IAE Business School (Argentina): Master of Business Administration
    - UES21 (Argentina): Bachelor of Advertising
    Fields of Expertise
    - Growth Strategy
    - Entrepreneurship
    - Marketing Technology
    Work Experience
    - RV, Marketing & Communications Agency (LATAM): General Manager. Growth
    strategy advisor to pharmaceutical companies like Bayer, Teva, and Pfizer.
    - Pax Mobile, software company, VP of growth.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free